The identification of CD4+ TCR specific for KRAS mutations provides the foundation for applying the CD4+ T-cell immunity to the adoptive transfer therapy and deepens the mechanism of CD4+ T cells in human anti-tumor immunity. This evidence concerns the gene CD4 and neoplasm.